Tumor localization and systemic absorption of intravesical instillation of radio-iodinated iododeoxyuridine in patients with bladder cancer

Rei K. Chiou, Glenn V. Dalrymple, Janina Baranowska-Kortylewicz, Karen P. Holdeman, Martin H. Schneiderman, Katherine A. Harrison, Rodney J. Taylor

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: We evaluated tumor uptake and systemic distribution of intravesically instilled iododeoxyuridine (IUdR) in patients with superficial bladder cancer. Materials and Methods: We performed 24 intravesical instillation studies in 11 patients with a mean age of 71 years. Radio- iodinated IUdR was administered through a Foley catheter. Gamma camera imaging was done after instillation and after 5 to 7 bladder irrigations. Tumor uptake was estimated by region of interest analysis. Bladder biopsy samples and surgical tumor specimens were tested for acid insoluble (deoxyribonucleic acid incorporated) radioactivity. Blood samples were obtained and analyzed for systemic absorption. Results: Imaging was positive in all patients with bladder cancer. Average tumor uptake plus or minus standard deviation was 0.185 ± 0.120% of the instilled dose. Preferential uptake of IUdR in the tumor was observed in all 6 patients undergoing tissue analysis. The tumor-to-normal bladder ratio ranged from 3.2 to 74,000 (median 202). Systemic absorption of IUdR was minimal. Blood sample analysis performed after intravesical instillation in all 11 cases revealed an average uptake of 3.2 x 10-5% instilled dose per ml. (range 0.69 x 10-5 to 6.7 x 10-5) in the systemic circulation. Instillation within 24 hours after transurethral bladder tumor resection in 5 cases resulted in a higher but not dangerous average systemic uptake of 7.3 x 10-4% instilled dose per ml. (range 1.3 x 10-5 to 2.6 x 10-3). Instillation 1 to 4 weeks after transurethral surgery in 8 cases resulted in no increased systemic absorption with an average blood level of 3.4 ± 1.8 x 10-5% instilled dose per ml. There was no detectable distribution of radioactivity into other organs, including the thyroid. We noted no evidence of systemic toxicity in the study. Conclusions: Intravesical instillation of radio-iodinated IUdR achieves selective localization in the bladder tumor with minimal uptake by the normal bladder and minimal systemic absorption. The use of intravesical IUdR therapy for bladder cancer appears to be promising and requires further study.

Original languageEnglish (US)
Pages (from-to)58-62
Number of pages5
JournalJournal of Urology
Volume162
Issue number1
DOIs
StatePublished - Jan 1 1999

Fingerprint

Idoxuridine
Intravesical Administration
Radio
Urinary Bladder Neoplasms
Urinary Bladder
Neoplasms
Radioactivity
Physiological Absorption
Radionuclide Imaging
Thyroid Gland
Catheters
Biopsy
Acids
DNA

Keywords

  • Bladder
  • Idoxuridine
  • Neoplasm, bladder
  • Radionuclide imaging

ASJC Scopus subject areas

  • Urology

Cite this

Tumor localization and systemic absorption of intravesical instillation of radio-iodinated iododeoxyuridine in patients with bladder cancer. / Chiou, Rei K.; Dalrymple, Glenn V.; Baranowska-Kortylewicz, Janina; Holdeman, Karen P.; Schneiderman, Martin H.; Harrison, Katherine A.; Taylor, Rodney J.

In: Journal of Urology, Vol. 162, No. 1, 01.01.1999, p. 58-62.

Research output: Contribution to journalArticle

Chiou, Rei K. ; Dalrymple, Glenn V. ; Baranowska-Kortylewicz, Janina ; Holdeman, Karen P. ; Schneiderman, Martin H. ; Harrison, Katherine A. ; Taylor, Rodney J. / Tumor localization and systemic absorption of intravesical instillation of radio-iodinated iododeoxyuridine in patients with bladder cancer. In: Journal of Urology. 1999 ; Vol. 162, No. 1. pp. 58-62.
@article{0ec4cd1146a84afeb4d95b16752563a0,
title = "Tumor localization and systemic absorption of intravesical instillation of radio-iodinated iododeoxyuridine in patients with bladder cancer",
abstract = "Purpose: We evaluated tumor uptake and systemic distribution of intravesically instilled iododeoxyuridine (IUdR) in patients with superficial bladder cancer. Materials and Methods: We performed 24 intravesical instillation studies in 11 patients with a mean age of 71 years. Radio- iodinated IUdR was administered through a Foley catheter. Gamma camera imaging was done after instillation and after 5 to 7 bladder irrigations. Tumor uptake was estimated by region of interest analysis. Bladder biopsy samples and surgical tumor specimens were tested for acid insoluble (deoxyribonucleic acid incorporated) radioactivity. Blood samples were obtained and analyzed for systemic absorption. Results: Imaging was positive in all patients with bladder cancer. Average tumor uptake plus or minus standard deviation was 0.185 ± 0.120{\%} of the instilled dose. Preferential uptake of IUdR in the tumor was observed in all 6 patients undergoing tissue analysis. The tumor-to-normal bladder ratio ranged from 3.2 to 74,000 (median 202). Systemic absorption of IUdR was minimal. Blood sample analysis performed after intravesical instillation in all 11 cases revealed an average uptake of 3.2 x 10-5{\%} instilled dose per ml. (range 0.69 x 10-5 to 6.7 x 10-5) in the systemic circulation. Instillation within 24 hours after transurethral bladder tumor resection in 5 cases resulted in a higher but not dangerous average systemic uptake of 7.3 x 10-4{\%} instilled dose per ml. (range 1.3 x 10-5 to 2.6 x 10-3). Instillation 1 to 4 weeks after transurethral surgery in 8 cases resulted in no increased systemic absorption with an average blood level of 3.4 ± 1.8 x 10-5{\%} instilled dose per ml. There was no detectable distribution of radioactivity into other organs, including the thyroid. We noted no evidence of systemic toxicity in the study. Conclusions: Intravesical instillation of radio-iodinated IUdR achieves selective localization in the bladder tumor with minimal uptake by the normal bladder and minimal systemic absorption. The use of intravesical IUdR therapy for bladder cancer appears to be promising and requires further study.",
keywords = "Bladder, Idoxuridine, Neoplasm, bladder, Radionuclide imaging",
author = "Chiou, {Rei K.} and Dalrymple, {Glenn V.} and Janina Baranowska-Kortylewicz and Holdeman, {Karen P.} and Schneiderman, {Martin H.} and Harrison, {Katherine A.} and Taylor, {Rodney J.}",
year = "1999",
month = "1",
day = "1",
doi = "10.1097/00005392-199907000-00015",
language = "English (US)",
volume = "162",
pages = "58--62",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Tumor localization and systemic absorption of intravesical instillation of radio-iodinated iododeoxyuridine in patients with bladder cancer

AU - Chiou, Rei K.

AU - Dalrymple, Glenn V.

AU - Baranowska-Kortylewicz, Janina

AU - Holdeman, Karen P.

AU - Schneiderman, Martin H.

AU - Harrison, Katherine A.

AU - Taylor, Rodney J.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Purpose: We evaluated tumor uptake and systemic distribution of intravesically instilled iododeoxyuridine (IUdR) in patients with superficial bladder cancer. Materials and Methods: We performed 24 intravesical instillation studies in 11 patients with a mean age of 71 years. Radio- iodinated IUdR was administered through a Foley catheter. Gamma camera imaging was done after instillation and after 5 to 7 bladder irrigations. Tumor uptake was estimated by region of interest analysis. Bladder biopsy samples and surgical tumor specimens were tested for acid insoluble (deoxyribonucleic acid incorporated) radioactivity. Blood samples were obtained and analyzed for systemic absorption. Results: Imaging was positive in all patients with bladder cancer. Average tumor uptake plus or minus standard deviation was 0.185 ± 0.120% of the instilled dose. Preferential uptake of IUdR in the tumor was observed in all 6 patients undergoing tissue analysis. The tumor-to-normal bladder ratio ranged from 3.2 to 74,000 (median 202). Systemic absorption of IUdR was minimal. Blood sample analysis performed after intravesical instillation in all 11 cases revealed an average uptake of 3.2 x 10-5% instilled dose per ml. (range 0.69 x 10-5 to 6.7 x 10-5) in the systemic circulation. Instillation within 24 hours after transurethral bladder tumor resection in 5 cases resulted in a higher but not dangerous average systemic uptake of 7.3 x 10-4% instilled dose per ml. (range 1.3 x 10-5 to 2.6 x 10-3). Instillation 1 to 4 weeks after transurethral surgery in 8 cases resulted in no increased systemic absorption with an average blood level of 3.4 ± 1.8 x 10-5% instilled dose per ml. There was no detectable distribution of radioactivity into other organs, including the thyroid. We noted no evidence of systemic toxicity in the study. Conclusions: Intravesical instillation of radio-iodinated IUdR achieves selective localization in the bladder tumor with minimal uptake by the normal bladder and minimal systemic absorption. The use of intravesical IUdR therapy for bladder cancer appears to be promising and requires further study.

AB - Purpose: We evaluated tumor uptake and systemic distribution of intravesically instilled iododeoxyuridine (IUdR) in patients with superficial bladder cancer. Materials and Methods: We performed 24 intravesical instillation studies in 11 patients with a mean age of 71 years. Radio- iodinated IUdR was administered through a Foley catheter. Gamma camera imaging was done after instillation and after 5 to 7 bladder irrigations. Tumor uptake was estimated by region of interest analysis. Bladder biopsy samples and surgical tumor specimens were tested for acid insoluble (deoxyribonucleic acid incorporated) radioactivity. Blood samples were obtained and analyzed for systemic absorption. Results: Imaging was positive in all patients with bladder cancer. Average tumor uptake plus or minus standard deviation was 0.185 ± 0.120% of the instilled dose. Preferential uptake of IUdR in the tumor was observed in all 6 patients undergoing tissue analysis. The tumor-to-normal bladder ratio ranged from 3.2 to 74,000 (median 202). Systemic absorption of IUdR was minimal. Blood sample analysis performed after intravesical instillation in all 11 cases revealed an average uptake of 3.2 x 10-5% instilled dose per ml. (range 0.69 x 10-5 to 6.7 x 10-5) in the systemic circulation. Instillation within 24 hours after transurethral bladder tumor resection in 5 cases resulted in a higher but not dangerous average systemic uptake of 7.3 x 10-4% instilled dose per ml. (range 1.3 x 10-5 to 2.6 x 10-3). Instillation 1 to 4 weeks after transurethral surgery in 8 cases resulted in no increased systemic absorption with an average blood level of 3.4 ± 1.8 x 10-5% instilled dose per ml. There was no detectable distribution of radioactivity into other organs, including the thyroid. We noted no evidence of systemic toxicity in the study. Conclusions: Intravesical instillation of radio-iodinated IUdR achieves selective localization in the bladder tumor with minimal uptake by the normal bladder and minimal systemic absorption. The use of intravesical IUdR therapy for bladder cancer appears to be promising and requires further study.

KW - Bladder

KW - Idoxuridine

KW - Neoplasm, bladder

KW - Radionuclide imaging

UR - http://www.scopus.com/inward/record.url?scp=0032845162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032845162&partnerID=8YFLogxK

U2 - 10.1097/00005392-199907000-00015

DO - 10.1097/00005392-199907000-00015

M3 - Article

VL - 162

SP - 58

EP - 62

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 1

ER -